Tags

Type your tag names separated by a space and hit enter

[Serum levels of soluble receptors for tumor necrosis factor in sarcoidosis].
Nihon Kyobu Shikkan Gakkai Zasshi. 1995 Aug; 33(8):850-5.NK

Abstract

Tumor necrosis factor alpha (TNF-alpha) has been shown to play an important role in granulomatous diseases, including sarcoidosis. TNF-alpha starts affecting cell function by binding to specific, high-affinity receptors on the cell surface, and two types of TNF-alpha receptors have been identified. Recently, soluble forms derived these cell surface receptors (sTNF-R type I and type II) have been shown to exist and have been investigated in several diseases. The levels of sTNF-R type I and type II in serum from patients with sarcoidosis were measured, and the clinical significance of sTNF-R was evaluated. The levels of both sTNF-R type I and type II were significantly higher in serum from patients with sarcoidosis (n = 36) than in serum from control subjects (n = 15): type I, 1.93 +/- 1.28 ng/ml vs 1.31 +/- 0.40 ng/ml, p < 0.01; type II, 3.48 +/- 2.60 ng/ml vs 1.56 +/- 0.35 ng/ml, p < 0.001. The levels of these receptors were significantly higher in patients with active sarcoidosis than in those with inactive sarcoidosis: type I, 2.43 +/- 1.83 ng/ml vs 1.57 +/- 0.45 ng/ml, p < 0.05; type 4.71 +/- 2.24 ng/ml vs 2.25 +/- 0.77 ng/ml, p < 0.01. The levels of sTNF-R type I and type II correlated significantly with the level of ACE, r = 0.70, p < 0.01; and r = 0.55, p < 0.05, respectively. We conclude that measurement of the levels of both types of sTNF-R may be useful in the evaluation of disease activity in sarcoidosis.

Authors+Show Affiliations

Kawaguchi H
Second Department of Internal Medicine, Nagoya City University, Japan.
Ina Y
No affiliation info available
Sato S
No affiliation info available
Ito S
No affiliation info available
Sugiura Y
No affiliation info available
Hasegawa Y
No affiliation info available
Takada K
No affiliation info available
Yamamoto M
No affiliation info available
Morishita M
No affiliation info available

MeSH

AdolescentAdultAgedBiomarkersFemaleHumansMaleMiddle AgedReceptors, Tumor Necrosis FactorSarcoidosisSolubilityTumor Necrosis Factor-alpha

Pub Type(s)

Clinical Trial
English Abstract
Journal Article

Language

jpn

PubMed ID

7474565

Citation

Kawaguchi, H, et al. "[Serum Levels of Soluble Receptors for Tumor Necrosis Factor in Sarcoidosis]." Nihon Kyobu Shikkan Gakkai Zasshi, vol. 33, no. 8, 1995, pp. 850-5.
Kawaguchi H, Ina Y, Sato S, et al. [Serum levels of soluble receptors for tumor necrosis factor in sarcoidosis]. Nihon Kyobu Shikkan Gakkai Zasshi. 1995;33(8):850-5.
Kawaguchi, H., Ina, Y., Sato, S., Ito, S., Sugiura, Y., Hasegawa, Y., Takada, K., Yamamoto, M., & Morishita, M. (1995). [Serum levels of soluble receptors for tumor necrosis factor in sarcoidosis]. Nihon Kyobu Shikkan Gakkai Zasshi, 33(8), 850-5.
Kawaguchi H, et al. [Serum Levels of Soluble Receptors for Tumor Necrosis Factor in Sarcoidosis]. Nihon Kyobu Shikkan Gakkai Zasshi. 1995;33(8):850-5. PubMed PMID: 7474565.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Serum levels of soluble receptors for tumor necrosis factor in sarcoidosis]. AU - Kawaguchi,H, AU - Ina,Y, AU - Sato,S, AU - Ito,S, AU - Sugiura,Y, AU - Hasegawa,Y, AU - Takada,K, AU - Yamamoto,M, AU - Morishita,M, PY - 1995/8/1/pubmed PY - 1995/8/1/medline PY - 1995/8/1/entrez SP - 850 EP - 5 JF - Nihon Kyobu Shikkan Gakkai zasshi JO - Nihon Kyobu Shikkan Gakkai Zasshi VL - 33 IS - 8 N2 - Tumor necrosis factor alpha (TNF-alpha) has been shown to play an important role in granulomatous diseases, including sarcoidosis. TNF-alpha starts affecting cell function by binding to specific, high-affinity receptors on the cell surface, and two types of TNF-alpha receptors have been identified. Recently, soluble forms derived these cell surface receptors (sTNF-R type I and type II) have been shown to exist and have been investigated in several diseases. The levels of sTNF-R type I and type II in serum from patients with sarcoidosis were measured, and the clinical significance of sTNF-R was evaluated. The levels of both sTNF-R type I and type II were significantly higher in serum from patients with sarcoidosis (n = 36) than in serum from control subjects (n = 15): type I, 1.93 +/- 1.28 ng/ml vs 1.31 +/- 0.40 ng/ml, p < 0.01; type II, 3.48 +/- 2.60 ng/ml vs 1.56 +/- 0.35 ng/ml, p < 0.001. The levels of these receptors were significantly higher in patients with active sarcoidosis than in those with inactive sarcoidosis: type I, 2.43 +/- 1.83 ng/ml vs 1.57 +/- 0.45 ng/ml, p < 0.05; type 4.71 +/- 2.24 ng/ml vs 2.25 +/- 0.77 ng/ml, p < 0.01. The levels of sTNF-R type I and type II correlated significantly with the level of ACE, r = 0.70, p < 0.01; and r = 0.55, p < 0.05, respectively. We conclude that measurement of the levels of both types of sTNF-R may be useful in the evaluation of disease activity in sarcoidosis. SN - 0301-1542 UR - https://www.unboundmedicine.com/medline/citation/7474565/[Serum_levels_of_soluble_receptors_for_tumor_necrosis_factor_in_sarcoidosis]_ L2 - http://www.diseaseinfosearch.org/result/6412 DB - PRIME DP - Unbound Medicine ER -